Answers are grounded in this paper and cite their sources.
Parkinson’s disease (PD) exhibits sex differences in prevalence and clinical phenotypes, yet their molecular basis remains unclear. We conducted a sex-stratified multi-omic integration combining gene-based association, transcriptome-wide association study (TWAS), and proteome-wide Mendelian randomization (PWMR) with colocalization, using sex-stratified genome-wide association data from the International Parkinson’s Disease Genomics Consortium and sex-combined data from the Global Parkinson’s Genetics Program. Prioritized candidates were further evaluated through MR with blood and brain eQTLs, plasma and cerebrospinal fluid (CSF) protein abundance, and pathway enrichment. We prioritized 102 candidates across 31 loci. Eleven genes reached significance across all three layers: SNCA, MAPT, CTSB in both sexes; CD160 as male-specific; GPNMB, LRRC37A2 as male-predominant; STX4, PRSS53 as female-predominant; and BST1, SCARB2 , and LGALS3 in sex-combined analysis only. CD160 and L3MBTL2 were previously unreported male-specific candidates. eQTL-based MR provided additional support for 86 of 97 testable candidates. Among 37 candidates with proteomic measurements, nine showed differential abundance in plasma, but none in CSF. Pathway enrichment showed sex-divergent pathways: male-specific immune signaling and SUMOylation versus female-specific chromatin remodeling. These findings support sex-dependent molecular contributions to PD susceptibility, layered on shared lysosomal and α-synuclein/tau axes, supporting sex-stratified approaches in biomarker discovery and therapeutic development.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: